IP Library Granted Patent US 8,268,635
Granted Patent B2
US 8,268,635 · App. 12/301,429 · Granted Sep 18, 2012

Methods of identifying agents that selectively activate p38 and/or NKkB signaling

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,268,635
App. No.
12/301,429
Granted
Sep 18, 2012
Kind
B2
Abstract

The present invention relates to a method of selectively modulating a signalling pathway of interest controlled by a cell receptor involved in signalling through multiple pathways. The method includes exposing the receptor to an agent that modulates signalling by the receptor through the signalling pathway of interest and does not substantially modulate signalling through one or more other signalling pathways controlled by the receptor.

Claims (8)

1. A method of identifying an agent that selectively activates p38 and/or NFkB signaling and does not substantially activate signaling through one or more of the JNK and/or ERK1/2 signaling pathways controlled by TNF Receptor-1 (TNFR1), said method comprising identifying an agent that binds to one or more of amino acids 209 to 211 of SEQ. ID NO: 1, wherein an agent that binds to said amino acids is identified as an agent that selectively activates p38 and/or NFkB signaling.

2. A method according to claim 1 , wherein the agent selectively activates p38 signaling and/or NFκB signaling upon binding of TNF-α to TNFR1.

3. A method of identifying an agent that selectively activates p38 and/or NFkB signaling downstream of TNF Receptor-1 (TNFR1), comprising:

(i) providing an intact cell with TNFR1 on its surface;

(ii) contacting said cell with an agent that binds to one or more of amino acids 209 to 211 of SEQ. ID NO: 1;

(iii) assaying the activation of the p38 and/or NFkB;

(iv) assaying the activation of JNK or ERK1/2; and

(v) selecting the agent that activates p38 and/or NFkB signaling pathway and does not substantially activate the JNK and/or ERK1/2 signaling pathway.

Priority Claims (2)
AU 2006902704 · May 19, 2006 · national
AU 2006906064 · Nov 1, 2006 · national
Continuity (1)
Related Publication 20090291899A1 · Nov 26, 2009